Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC

StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a multicenter, open-label, single-arm phase 2 study evaluating the efficacy and safety of ivonescimab combined with paclitaxel polymeric micelles in adults with recurrent or refractory small cell lung cancer after failure of platinum-based chemotherapy and anti-PD-1/PD-L1 therapy.
Trial Details
NCT Number NCT07819591
Lead Sponsor Shaodong Hong
Collaborators: Akesobio, Shanghai Yizhong Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 SCLC, Recurrent
Related terms Recurrence, Small Cell Lung Carcinoma
Enrollment 47 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov